Amgen Gets FDA Approval for Small-Cell Lung-Cancer Treatment
By Ben Glickman
Amgen on Thursday received approval from U.S. regulators for its drug to treat a form of late-stage lung-cancer.
The pharmaceutical company said that Imdelltra, an immunotherapy, was approved by the U.S. Food and Drug Administration for treating adults with extensive-stage small-cell lung cancer.
The indication is specifically for cases with progression on or after platinum-based chemotherapy.
Amgen's treatment received accelerated approval, meaning it was approved based on a surrogate endpoint in a trial.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
May 16, 2024 19:21 ET (23:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now